Journal article
P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)
Paul G Richardson, Suzanne Trudel, Natalie S Callander, Ajay Nooka, Kevin Song, Katarina Uttervall, Monique C Minnema, Paula Rodríguez-Otero, Herbert Struemper, Anne Yeakey, Rocio Montes de Oca, L Mary Smith, Nicola Jackson, Morrys Kaisermann, Ellie Im, Frank G Basile, Christoph M Ahlers, Beata Holkova, Ira Gupta, Brandon E Kremer Show all
Clinical Lymphoma Myeloma and Leukemia | Elsevier BV | Published : 2021
Abstract
Background Single-agent belamaf, a B-cell maturation antigen-targeting antibody-drug conjugate, induced durable responses with a manageable safety profile in patients with RRMM at 13 months of follow-up (DREAMM-2; NCT03525678). The unique multimodal mechanisms of action (MoAs) of belamaf, in combination with MoAs of selected agents, have the potential to achieve synergistic effects in RRMM to further enhance the benefit-risk profile. Belamaf is being evaluated in DREAMM-5 in various lines of treatment, as monotherapy or in combination with other agents. Methods DREAMM-5 (NCT04126200) is a phase 1/2 platform study that utilizes a master protocol with separate sub-studies comprised of sequenti..
View full abstract